Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-caryophyllene is a natural bicyclic sesquiterpene that occurs widely in nature. It is notable for having a cyclobutane ring and a trans-double bond in a 9-membered ring, both rarities in nature. Beta-caryophyllene functions as a selective non-psychoactive CB2 receptor agonist with a binding affinity of Ki = 155 nM and approximately 60-fold selectivity for CB2 over CB1 receptors. It exhibits potent anti-inflammatory, antimicrobial, antibacterial, and antioxidant properties. Research indicates it may help relieve anxiety and pain, reduce cholesterol, prevent osteoporosis, and treat seizures. It has also shown potential benefits for brain health, including possible protection against Alzheimer's disease, and may have anticancer effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-caryophyllene.